Literature DB >> 23550937

Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.

Andrew Brown1, Qi Shi, Terry W Moore, Younghyoun Yoon, Andrew Prussia, Clinton Maddox, Dennis C Liotta, Hyunsuk Shim, James P Snyder.   

Abstract

Curcumin is a biologically active component of curry powder. A structurally related class of mimetics possesses similar anti-inflammatory and anticancer properties. Mechanism has been examined by exploring kinase inhibition trends. In a screen of 50 kinases relevant to many forms of cancer, one member of the series (4, EF31) showed ≥85% inhibition for 10 of the enzymes at 5 μM, while 22 of the proteins were blocked at ≥40%. IC50 values for an expanded set of curcumin analogues established a rank order of potencies, and analyses of IKKβ and AKT2 enzyme kinetics for 4 revealed a mixed inhibition model, ATP competition dominating. Our curcumin mimetics are generally selective for Ser/Thr kinases. Both selectivity and potency trends are compatible with protein sequence comparisons, while modeled kinase binding site geometries deliver a reasonable correlation with mixed inhibition. Overall, these analogues are shown to be pleiotropic inhibitors that operate at multiple points along cell signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23550937      PMCID: PMC3927397          DOI: 10.1021/jm4002692

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  44 in total

1.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

Review 2.  Commentary: Novel therapies for cancer: why dirty might be better.

Authors:  Tito Fojo
Journal:  Oncologist       Date:  2008-03

3.  Models for predicting IKKA and IKKB blockade.

Authors:  Haipeng Hu; James P Snyder
Journal:  J Chem Inf Model       Date:  2012-12-04       Impact factor: 4.956

4.  Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin.

Authors:  Shih-Han Sun; Hsiu-Chen Huang; Cheng Huang; Jen-Kun Lin
Journal:  Eur J Pharmacol       Date:  2012-06-15       Impact factor: 4.432

5.  Targeting the BMK1 MAP kinase pathway in cancer therapy.

Authors:  Qingkai Yang; Jiing-Dwan Lee
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

Review 6.  The targets of curcumin.

Authors:  Hongyu Zhou; Christopher S Beevers; Shile Huang
Journal:  Curr Drug Targets       Date:  2011-03-01       Impact factor: 3.465

7.  Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition.

Authors:  Masayoshi Yamaguchi; Terry W Moore; Aiming Sun; James P Snyder; Mamoru Shoji
Journal:  Integr Biol (Camb)       Date:  2012-07-03       Impact factor: 2.192

Review 8.  Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research.

Authors:  Julie S Jurenka
Journal:  Altern Med Rev       Date:  2009-06

9.  Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism.

Authors:  Aiming Sun; Yang J Lu; Haipeng Hu; Mamoru Shoji; Dennis C Liotta; James P Snyder
Journal:  Bioorg Med Chem Lett       Date:  2009-10-08       Impact factor: 2.823

10.  Exploiting the promiscuity of imatinib.

Authors:  Shun J Lee; Jean Y J Wang
Journal:  J Biol       Date:  2009-04-15
View more
  8 in total

1.  Liver S9 Fraction-Derived Metabolites of Curcumin Analogue UBS109.

Authors:  Terry W Moore; Shijun Zhu; Ryan Randolph; Mamoru Shoji; James P Snyder
Journal:  ACS Med Chem Lett       Date:  2014-01-10       Impact factor: 4.345

2.  Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis.

Authors:  Patrick R Baldwin; Analise Z Reeves; Kimberly R Powell; Ruth J Napier; Alyson I Swimm; Aiming Sun; Kyle Giesler; Bettina Bommarius; Thomas M Shinnick; James P Snyder; Dennis C Liotta; Daniel Kalman
Journal:  Eur J Med Chem       Date:  2015-01-10       Impact factor: 6.514

3.  Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents.

Authors:  Nawras Samaan; Qiu Zhong; Jayjoel Fernandez; Guanglin Chen; Ali M Hussain; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Eur J Med Chem       Date:  2014-01-29       Impact factor: 6.514

Review 4.  Eliminating the heart from the curcumin molecule: monocarbonyl curcumin mimics (MACs).

Authors:  Dinesh Shetty; Yong Joon Kim; Hyunsuk Shim; James P Snyder
Journal:  Molecules       Date:  2014-12-24       Impact factor: 4.411

5.  Effects of green synthesised silver nanoparticles (ST06-AgNPs) using curcumin derivative (ST06) on human cervical cancer cells (HeLa) in vitro and EAC tumor bearing mice models.

Authors:  Kalaimathi Murugesan; Jinsha Koroth; Padma Priya Srinivasan; Amrita Singh; Sanjana Mukundan; Subhas S Karki; Bibha Choudhary; Chhitar M Gupta
Journal:  Int J Nanomedicine       Date:  2019-07-16

Review 6.  Perspectives for synthetic curcumins in chemoprevention and treatment of cancer: An update with promising analogues.

Authors:  Adeoluwa Adeluola; Abu Hasanat Md Zulfiker; Daniel Brazeau; A R M Ruhul Amin
Journal:  Eur J Pharmacol       Date:  2021-06-17       Impact factor: 5.195

7.  Synthesis and evaluation of bisbenzylidenedioxotetrahydrothiopranones as activators of endoplasmic reticulum (ER) stress signaling pathways and apoptotic cell death in acute promyelocytic leukemic cells.

Authors:  Kheng-Lin Tan; Azhar Ali; Yuhong Du; Haian Fu; Hai-Xiao Jin; Tan-Min Chin; Matiullah Khan; Mei-Lin Go
Journal:  J Med Chem       Date:  2014-07-11       Impact factor: 7.446

8.  The Curcumin Analog CH-5 Exerts Anticancer Effects in Human Osteosarcoma Cells via Modulation of Transcription Factors p53/Sp1.

Authors:  Felipe Teixeira Lima; Viviane Seba; Gabriel Silva; Guilherme Silva Torrezan; Carlos Roberto Polaquini; Vitor Caressato Pinhanelli; Seung J Baek; Ana Lúcia Fachin; Luis Octavio Regasini; Mozart Marins
Journal:  Int J Mol Sci       Date:  2018-06-29       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.